anticancer

Exemestane (commonly known by the brand name Aromasin) is an aromatase inhibitor used to treat hormone-receptor-positive breast cancer in postmenopausal women. It works by significantly lowering estrogen levels in the body, which slows or halts the growth of cancer cells that rely on estrogen to multiply.

Erdafitinib (brand name Balversa) is an oral, targeted cancer medication used to treat adults with locally advanced or metastatic urothelial carcinoma (bladder cancer) that has specific FGFR3 or FGFR2 genetic alterations. It acts as a pan-fibroblast growth factor receptor (FGFR) inhibitor, disrupting cancer cell growth and survival.Indications & UseTarget Population: Patients with susceptible FGFR3 or FGFR2 genetic alterations.Treatment History: Used after prior platinum-containing chemotherapy fails.Approval Status: Granted accelerated approval by the FDA.Administration: Taken orally, usually as an 8 mg daily dose, with potential adjustment to 9 mg based on phosphate levels.